Positive News SentimentPositive NewsNASDAQ:VIGL Vigil Neuroscience (VIGL) Stock Price, News & Analysis $1.68 -0.10 (-5.34%) As of 02:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vigil Neuroscience Stock (NASDAQ:VIGL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vigil Neuroscience alerts:Sign Up Key Stats Today's Range$1.65▼$1.7850-Day Range$1.75▼$3.0352-Week Range$1.49▼$6.06Volume59,533 shsAverage Volume467,990 shsMarket Capitalization$78.64 millionP/E RatioN/ADividend YieldN/APrice Target$16.25Consensus RatingBuy Company OverviewVigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.Read More… Remove Ads Vigil Neuroscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreVIGL MarketRank™: Vigil Neuroscience scored higher than 81% of companies evaluated by MarketBeat, and ranked 195th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingVigil Neuroscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVigil Neuroscience has only been the subject of 3 research reports in the past 90 days.Read more about Vigil Neuroscience's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vigil Neuroscience are expected to grow in the coming year, from ($2.07) to ($2.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vigil Neuroscience is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vigil Neuroscience is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVigil Neuroscience has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Vigil Neuroscience's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.85% of the float of Vigil Neuroscience has been sold short.Short Interest Ratio / Days to CoverVigil Neuroscience has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vigil Neuroscience has recently decreased by 25.64%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVigil Neuroscience does not currently pay a dividend.Dividend GrowthVigil Neuroscience does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.85% of the float of Vigil Neuroscience has been sold short.Short Interest Ratio / Days to CoverVigil Neuroscience has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vigil Neuroscience has recently decreased by 25.64%, indicating that investor sentiment is improving significantly. News and Social Media3.7 / 5News Sentiment1.58 News SentimentVigil Neuroscience has a news sentiment score of 1.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Vigil Neuroscience this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for VIGL on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat Follows5 people have added Vigil Neuroscience to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vigil Neuroscience insiders have not sold or bought any company stock.Percentage Held by Insiders33.03% of the stock of Vigil Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.64% of the stock of Vigil Neuroscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vigil Neuroscience's insider trading history. Receive VIGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vigil Neuroscience and its competitors with MarketBeat's FREE daily newsletter. Email Address VIGL Stock News HeadlinesVigil Neuroscience files to sell 5.38M shares of common stock for holdersApril 1 at 2:24 AM | markets.businessinsider.comVigil Neuroscience price target lowered to $14 from $17 at H.C. WainwrightMarch 14, 2025 | markets.businessinsider.comElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to help build human colonies on the Red Planet. And here on Earth? Optimus is about to change everything.April 1, 2025 | InvestorPlace (Ad)Vigil Neuroscience price target lowered to $13 from $24 at WedbushMarch 14, 2025 | markets.businessinsider.comVigil Neuroscience Faces Market Risks from Preferred Stock Issuance and Potential Share DilutionMarch 14, 2025 | tipranks.comVigil Neuroscience, Inc.: Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business UpdatesMarch 13, 2025 | finanznachrichten.deVigil Neuroscience reports Q4 EPS (57c), consensus (47c)March 13, 2025 | markets.businessinsider.comVigil Neuroscience sees cash runway into 2026March 13, 2025 | markets.businessinsider.comSee More Headlines VIGL Stock Analysis - Frequently Asked Questions How have VIGL shares performed this year? Vigil Neuroscience's stock was trading at $1.70 at the beginning of the year. Since then, VIGL shares have increased by 2.1% and is now trading at $1.7350. View the best growth stocks for 2025 here. How were Vigil Neuroscience's earnings last quarter? Vigil Neuroscience, Inc. (NASDAQ:VIGL) announced its quarterly earnings results on Thursday, March, 13th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.49) by $0.08. When did Vigil Neuroscience IPO? Vigil Neuroscience (VIGL) raised $112 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 7,000,000 shares at $15.00-$17.00 per share. How do I buy shares of Vigil Neuroscience? Shares of VIGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vigil Neuroscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vigil Neuroscience investors own include NVIDIA (NVDA), Meta Platforms (META), Exxon Mobil (XOM), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Home Depot (HD). Company Calendar Last Earnings3/13/2025Today4/01/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VIGL CIK1827087 Webvigilneuro.com Phone857-254-4445FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$16.25 High Stock Price Target$22.00 Low Stock Price Target$13.00 Potential Upside/Downside+812.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-83.89% Return on Assets-65.34% Debt Debt-to-Equity RatioN/A Current Ratio3.72 Quick Ratio3.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.24 per share Price / Book0.55Miscellaneous Outstanding Shares46,672,000Free Float27,377,000Market Cap$83.08 million OptionableNot Optionable Beta1.82 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:VIGL) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredLive Footage From Elon Musk’s “Area 51”What’s happening inside this nondescript building in South Memphis is so incredible… That Elon’s competitor...Brownstone Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored“Massive Financial Reset Is Coming”The U.S. markets will see a massive reset, beginning days from now. But the "reset" isn't what you might ex...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vigil Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vigil Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.